Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non‐allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose‐finding Phase II trials is emphasized. Although methodologically insulated from the variability of natural pollen exposure, chamber models remain confined to supporting secondary, rather than primary, endpoints in Phase III registration trials. The need for further validation in comparison with field exposure is clearly mandated. On this basis, the European Academy of Allergy and Clinical Immunology (EAACI) initiated a Task Force in 2015 charged to gain a better understanding of how AECs can generate knowledge about respiratory allergies and can contribute to the clinical development of treatments. Researchers working with AECs worldwide were asked to provide technical information in eight sections: (i) dimensions and structure of the AEC, (ii) AEC staff, (iii) airflow, air processing, and operating conditions, (iv) particle dispersal, (v) pollen/particle counting, (vi) safety and non‐contamination measures, (vii) procedures for symptom assessments, (viii) tested allergens/substances and validation procedures. On this basis, a minimal set of technical requirements for AECs applied to the field of allergology is proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Devillier, P., Montagut, A., Mélac, M., Galvain, S., Jean-Alphonse, S., Van Overtvelt, L., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.006 · Cited by 175 · cited 1×
“Reproducibility and consistency have been proven (42-44).”
Self-citationZieglmayer, P., Focke-Tejkl, M., Schmutz, R., Lemell, P., Zieglmayer, R., Weber, M., Kiss, R., Blatt, K., Valent, P., Stolz, F., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.022 · Cited by 138
Self-citationKrug, N., Loedding, H., Hohlfeld, J. M., Larbig, M., Buckendahl, A., Badorrek, P., Geldmacher, H., Behnke, W., Dunkhorst, W., Windt, H., et al. (2003) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2003.01810.x · Cited by 73
Self-citationRösner-Friese, K., Kaul, S., Vieths, S., & Pfaar, O. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.045 · Cited by 66 · cited 4×
“The regulatory environment for AECs varies across Europe, Asia, and the Americas.2 Allergen exposure chambers are not classifiable as medical devices (according to the Medical Device Directive (Directive 93/42/EEC) or medicinal products (according to Directive 2001/83/EC), and so a well- established regulatory framewo…”
BackgroundInfluentialSelf-citationZuberbier, T., Abelson, M. B., Akdis, C. A., Bachert, C., Berger, U., Bindslev-Jensen, C., Boelke, G., Bousquet, J., Canonica, G. W., Casale, T. B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.08.025 · Cited by 40
Self-citationEffects of omalizumab on changes in pulmonary function induced by controlled cat room challenge
Corren, J., Wood, R. A., Patel, D., Zhu, J., Yegin, A., Dhillon, G., & Fish, J. E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.043 · Cited by 38 · cited 1×
“Those with moderate asthma can be included in for very specific studies with one-by-one assessment by a physician and a paramedic on site throughout the exposure and follow-up period (37).”
BackgroundZieglmayer, P., Zieglmayer, R., Bareille, P., Rousell, V., Salmon, E., & Horak, F. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802155792 · Cited by 35 · cited 1×
“Reproducibility and consistency have been proven (42-44).”
Self-citationValidation Study of the OHIO Chamber in Patients with Japanese Cedar Pollinosis
Hashiguchi, K., Tang, H., Fujita, T., Suematsu, K., Tsubaki, S., Nagakura, H., Kitajima, S., Gotoh, M., & Okubo, K. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000189197 · Cited by 31 · cited 1×
“We determined that 8000 grains/m3 of Japanese cedar pollen and 12000 grains/m3 of cypress pollen are sufficient to induce symptoms (39).”
BackgroundLueer, K., Biller, H., Casper, A., Windt, H., Mueller, M., Badorrek, P., Haefner, D., Framke, T., Koch, A., Ziehr, H., et al. (2016) · Allergy · doi:10.1111/all.12947 · Cited by 22
Self-citation
Cited by
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Self-citationEAACI Molecular Allergology User's Guide 2.0
Dramburg, S., Hilger, C., Santos, A. F., de las Vecillas, L., Aalberse, R. C., Acevedo, N., Aglas, L., Altmann, F., Arruda, K. L., Asero, R., et al. (2023) · Pediatric Allergy and Immunology · doi:10.1111/pai.13854 · Cited by 298
Self-citationMechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation
Sahiner, U. M., Giovannini, M., Escribese, M. M., Paoletti, G., Heffler, E., Alvaro Lozano, M., Barber, D., Canonica, G. W., & Pfaar, O. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050845 · Cited by 66
Self-citationBergmann, K.-C., Raab, J., Krause, L., Becker, S., Kugler, S., Zuberbier, T., Roth-Walter, F., Jensen-Jarolim, E., Kramer, M. F., & Graessel, A. (2022) · Allergo Journal International · doi:10.1007/s40629-021-00197-z · Cited by 12
Self-citation
Metadata
- Authors
- Pfaar, O., Bergmann, K., Bonini, S., Compalati, E., Domis, N., de Blay, F., de Kam, P., Devillier, P., Durham, S. R., Ellis, A. K., Gherasim, A., Haya, L., Hohlfeld, J. M., Horak, F., Iinuma, T., Jacobs, R. L., Jacobi, H. H., Jutel, M., Kaul, S., Kelly, S., Klimek, L., Larché, M., Lemell, P., Mahler, V., Nolte, H., Okamoto, Y., Patel, P., Rabin, R. L., Rather, C., Sager, A., Salapatek, A. M., Sigsgaard, T., Togias, A., Willers, C., Yang, W. H., Zieglmayer, R., Zuberbier, T., & Zieglmayer, P.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2021-11-28
- Volume
- 76
- Issue
- 12
- Pages
- 3589-3612
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W3165649735
- Cited by
- 39
- References
- 9
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. https://app.cochat.ai/papers/10.1111/all.14957
- The paper
- Pfaar, O., Bergmann, K., Bonini, S., Compalati, E., Domis, N., de Blay, F., de Kam, P., Devillier, P., Durham, S. R., Ellis, A. K., Gherasim, A., Haya, L., Hohlfeld, J. M., Horak, F., Iinuma, T., Jacobs, R. L., Jacobi, H. H., Jutel, M., Kaul, S., . . . Zieglmayer, P. (2021). Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. Allergy. https://doi.org/10.1111/all.14957
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.